Anticoagulation in Deep Venous Thrombosis: Current Trends in the Era of Non-Vitamin K Antagonists Oral Anticoagulants.

Anticoagulation in Deep Venous Thrombosis: Current Trends in the Era of Non-Vitamin K Antagonists Oral Anticoagulants. Curr Pharm Des. 2020 Apr 20;: Authors: Papakonstantinou PE, Tsioufis C, Konstantinidis D, Iliakis P, Leontsinis I, Tousoulis D Abstract Anticoagulation therapy is the cornerstone of treatment in acute vein thrombosis (DVT)and it aims to reduce symptoms, thrombus extension, DVT recurrences, and mortality.The treatment for DVT depends on its anatomical extent among other factors. Anticoagulation therapy for proximal DVT is clearly recommended (at least for 3 months), while AT for isolated distal DVT should be considered, especially in the presence of high thromboembolic risk factors.The optimal anticoagulant and duration of therapy are determined by the clinical assessment taking into account the thromboembolic and bleeding risk in each patient in a case-by-case decision making. Non-Vitamin K antagonists oral anticoagulants (NOACs) were a revolution in the anticoagulation management of DVT. Nowadays, NOACs areconsidered as first line therapy in the anticoagulation therapy for DVT and are recommended as the preferred anticoagulant agents in DVT by most scientific societies. NOACs offer a simple route of administration (oral agents), a rapid onset-offset of their action along with a good efficacy and safety profile in comparison with Vitamin K Antagonists (VKAs). However, there are issues about their efficacy and safety ...
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research